Background {#Sec1}
==========

Ligament, muscle, and tendon injuries produce pain, loss of function, instability, and secondary osteoarthritis \[[@CR1], [@CR2]\]. Traditionally, these injuries have been managed using activity modification; physical therapy; pharmacological agents, such as non-steroidal anti-inflammatory drugs, corticosteroids, viscosupplementation, and narcotics; and surgical procedures when conservative management fails \[[@CR3]\]. These modalities have limitations and potential side effects \[[@CR4]\].

Over the last decade, there has been an increased interest in the use of biologics for regenerative medicine applications \[[@CR5]\]. Biologics currently used in clinical practice include platelet-rich plasma, bone marrow aspirate, adipose tissue aspirate, amniotic fluid, amniotic membrane, umbilical cord-derived Wharton's jelly and cord blood \[[@CR6], [@CR7]\]. The healing capabilities of these products are attributed to the presence of stem cells, growth factors, cytokines, hyaluronic acid, and/or extracellular vesicles including exosomes \[[@CR8]\].

Stem cells, including mesenchymal stem cells isolated from bone marrow, periosteum, adipose tissue, trabecular bone, and deciduous teeth, have produced marked interest for their applications to regenerative medicine \[[@CR7]\]. Stem cells are able to differentiate along specific lineage in response to signal transduction mediated by growth factors and cytokines \[[@CR8]\]. Growth factors and cytokines often have overlapping activities. They are able to target mesenchymal, endothelial, and epithelial cells, and can act in an autocrine or paracrine manner \[[@CR8]\]. In addition, one cytokine can stimulate the synthesis and release of other cytokines leading to a network of interacting molecules. This complex network of cytokines and growth factors can guide cell division, differentiation, and regeneration of different tissues and organs \[[@CR8]\].

Hyaluronic acid, a polysaccharide found in most tissues, is a major component of extracellular matrix of the skin, joints, and eyes \[[@CR9]\]. Hyaluronic acid has been used to manage knee osteoarthritis via its chondroprotection, proteoglycan and glycosaminoglycan synthesis, and anti-inflammatory, mechanical, subchondral, and analgesic actions \[[@CR10]\].

Exosomes are small extracellular vesicles with diameter ranging from \~ 30 to 150 nm, developed from a sequential process of multivesicular body membrane remodeling \[[@CR11]\]. Exosomes are found in multiple body fluids including blood plasma, amniotic fluid, and Wharton's jelly \[[@CR12], [@CR13]\]. Exosomes are secreted from several cell types including stem cells and represent an important mode of intercellular communications \[[@CR13]\]. Recently, exosomes have also emerged as an attractive cell-free therapeutic alternative that holds great regenerative potential \[[@CR14]\].

The increasing applications of biologic therapies for regenerative medicine have led to considerable marketing, patient demand, and clinical utilization \[[@CR5]\]. To be compliant in the United States (U.S.), biologics that adhere to the U.S. Food and Drug Administration (FDA) regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated under title 21, part 1271 of the Code of Federal Regulations (CFR), must meet all the criteria under section 361 of Public Health Safety (PHS) Act to be regulated solely under this section \[[@CR5]\]. According to this regulation, HCT/Ps must meet the criteria of being minimally manipulated, for homologous use only, not to be combination products, to have no systemic effect, and to be non-dependent on the metabolic activity of the living cells \[[@CR5]\]. Despite increased use, there is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid and extracellular vesicles including exosomes present in these products, and, more specifically, umbilical cord-derived Wharton's jelly.

Wharton's jelly is a primordial mucous connective tissue of the umbilical cord present between the amniotic epithelium and the umbilical vessels \[[@CR15]\]. The key role of Wharton's jelly is to provide cushion, protection, and structural support to umbilical vessels by preventing their compression, torsion, and bending \[[@CR15]\]. The umbilical vessels also provide bi-directional flow of oxygen, glucose, and amino acids to developing fetus and aids in depleting the fetus of carbon dioxide and other waste products \[[@CR15]\]. This gelatinous substance contains primitive mesenchymal stem cells (MSC) \[[@CR15]\] and yields the highest concentration of MSC per milliliter of other allogenic tissues \[[@CR16]\]. Wharton's jelly MSC may be more effective than MSC from adult tissues in the treatment of several conditions, and though safe and efficacious, more studies are required to justify their routine use in the clinics \[[@CR17]\]. Wharton's jelly also contains high amounts of extracellular matrix components, including collagen, hyaluronic acid, and sulfated proteoglycans \[[@CR18]\].

The present study reports the results of experiments aimed to characterize a novel umbilical cord-derived Wharton's jelly formulation and to evaluate the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes. We hypothesized that numerous growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes are present in Wharton's jelly; all may play a role in reducing inflammation and pain and augment healing of musculoskeletal injuries.

Methods {#Sec2}
=======

Human umbilical cords were obtained from consenting caesarian section donors following standards established by the FDA and the American Association of Tissue Banks. Donors underwent comprehensive medical, social and blood testing prior to donation. Infectious disease testing was performed at an independent certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493 and the FDA. Each donor was tested for HIV I/II Plus O Ab (antibodies to human immunodeficiency virus type 1 & 2), HBsAg (HEPATITIS B surface antigen), HBcAb (hepatitis B core Antibody), HBcTotal, HCV NAT (hepatitis C virus nucleic acid test), HTLV (Human T-lymphotropic virus) I/II Ab, RPR (Rapid plasma reagin) syphilis screening - nontreponemal, CMV (*Cytomegalovirus*), HIV-1/HCV (hepatitis C antibody)/HBV NAT Ultrio, WNV (West Nile Virus) NAT.

The procured umbilical cord was rinsed with saline followed by the removal of blood vessels. The Wharton's jelly was then isolated from the remaining umbilical cord and formulated into an injectable form using proprietary steps for which patent is pending. All the processing was performed under aseptic conditions. This methodology intends to preserve the structural integrity of Wharton's jelly and does not include use of digestive enzymes, use of cryoprotectants such as dimethyl sulfoxide (DMSO), or isolation and in vitro expansion of cells. This formulation is prepared according to the criteria of minimal manipulation by FDA, does not include any combination products, and is not intended to depend on the metabolic activity of living cells.

A total of 60 samples from three different batches (20 samples per batch) were tested for sterility at an independent CLIA accredited laboratory, Eurofins VRL Laboratories (Centennial, CO, USA), under United States Pharmacopeia Chapter 71 - Sterility Testing guidelines. Six randomly selected samples from two different batches were sent to an independent laboratory, RayBiotech (Norcross, Georgia, USA), and were analyzed for the presence of growth factors and cytokines using Quantibody® Human Growth Factor Array 1 and Quantibody® Human Inflammation Array 3 respectively. The signals were visualized using Innopsys InnoScan (Carbonne, France) at Cy3 wavelength (\~ 550-nm excitation, \~ 570-nm emission). Data were analyzed using Q-Analyzer tool and the concentration of cytokines was determined using serial standard curve provided by the manufacturer (RayBiotech, Norcross, Georgia, USA). In addition, six randomly selected samples from two different batches were analyzed for the presence of hyaluronic acid using Hyaluronan Quantikine ELISA (enzyme-linked immunosorbent assay) kit (R&D systems, Minneapolis, MN, USA) according to the manufacturer's protocol.

Twelve randomly selected samples from the three different batches were sent to an independent laboratory, Extracellular Vesicle Core at Children's Hospital Los Angeles (California, USA), and were analyzed by nanoparticle tracking analysis for the presence of particles in the extracellular vesicle size range using Malvern Panalytical Nanosight NS300. These samples were also analyzed after staining with a general fluorescent membrane marker, CellMask Orange™ (Thermo Fisher Scientific, Waltham, MA, USA), as previously described \[[@CR19]\].

Results {#Sec3}
=======

All samples passed the sterility test. Growth factors, including, Insulin-like growth factor binding proteins (IGFBP) 1, 2, 3, 4, and 6, transforming growth factor alpha (TGF-α), and platelet-derived growth factor-AA (PDGF-AA) were detected in the formulated Wharton's jelly (Table [1](#Tab1){ref-type="table"}). Table 1Growth factors (GFs) expressed in the formulated Wharton's jellyGrowth factorsAverage amount (pg/mL)IGFBP-3Insulin-like growth factor binding proteins 324,985.5IGFBP-4Insulin-like growth factor binding proteins 412,302IGFBP-6Insulin-like growth factor binding proteins 67711.1IGFBP-2Insulin-like growth factor binding proteins 26900.6IGFBP-1Insulin-like growth factor binding proteins 15211.4TGF-αTransforming growth factor alpha311.4HGFHepatocyte growth factor266.6FGF-7Fibroblast growth factor102.2EG-VEGFEndocrine gland-derived vascular endothelia growth32.2PDGF-AAPlatelet-derived growth factor AA31.9VEGF R3Vascular endothelia growth factor receptor 316.8VEGFVascular endothelia growth factor14.4β-NGFBeta nerve growth factor12.8

The expression of several immunomodulatory cytokines, such as RANTES (regulated on activation, normal T cell expressed and secreted), interleukin 6 receptor (IL-6R), interleukin 16 (IL-16), and interferon gamma (IFN-γ) was also detected (Table [2](#Tab2){ref-type="table"}). Table 2Immunomodulatory cytokines expressed in the formulated Wharton's jellyImmunomodulatory cytokinesAverage amount (pg/mL)RANTESRegulated upon activation, normally T-expressed, and secreted; aka C-C motif chemokine ligand 5 (CCL5)551.0IL-6RInterleukin 6 receptor53.3MIP-1DMacrophage inflammatory protein 5; aka C-C motif chemokine ligand15 (CCL15)44.9SCF RStem cell factor, aka KIT Proto-oncogene receptor tyrosine Kinase40.3MCSFMacrophage colony-stimulating factor 112.2IL-16Interleukin 168.7I-309C-C motif chemokines ligand1 (CCL1)3.1IFN-γInterferon gamma1.8IL-1βInterleukin 1 beta1.3EOTAXINC-C motif chemokine ligand 11, 24, 26 (CC11, 24, 26)1.3

Additionally, the expression of pro-inflammatory cytokines such as macrophage colony stimulating factor (MCSF), macrophage stimulating protein 1-alpha (MIP-1α); anti-inflammatory cytokines, such as tumor necrosis factor receptor superfamily member 1A and 1B (TNF-RI and TNF-RII), interleukin 1 receptor antagonist (IL-1RA); and homeostatic cytokines, such as tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) was also observed (Table [3](#Tab3){ref-type="table"}). Table 3Pro-inflammatory, anti-inflammatory and homeostatic cytokines expressed in the formulated Wharton's jellyAverage amount (pg/mL)Pro-inflammatory cytokinesMCSFMacrophage colony-stimulating factor930.8MIP-1αMacrophage-stimulating protein 1-alpha; aka C-C motif chemokine ligand 3 (CCL3)1.2Anti-inflammatory cytokinesTNF-RITumor necrosis factor receptor superfamily member 1A191.6TNF-RIITumor necrosis factor, member 1B89.8IL-1RAInterleukin 1 receptor antagonist58.8Homeostatic cytokinesTIMP-2Tissue inhibitor of metalloproteinases 28663.6TIMP-1Tissue inhibitor of metalloproteinases 17386.7

Cytokines associated with wound healing including intercellular adhesion molecule 1 (ICAM-1), granulocyte-stimulating factor (G-CSF), growth differentiation factor 15 (GDF-15), and regenerative properties such as growth hormone (GH) were also expressed (Table [4](#Tab4){ref-type="table"}). Table 4Wound-healing and regenerative cytokines expressed in the formulated Wharton's jellyAverage amount (pg/mL)Wound-healing cytokinesICAM-1Intercellular adhesion molecule-11554.9MCP-1Monocyte chemotactic protein-1, aka CC motif chemokine ligand 2 (CCL2 Gene)119.0G-CSFGranulocyte-stimulating factor, aka Colony-stimulating factor 3 (CSF3)91.6GDF-15Growth differentiation factor 1589.2NT-4Neurotropin-433Regenerative cytokinesGHGrowth hormone or somatotropin, aka human growth hormone (hGH or HGH)31.1GDNFGlia cell-derived neurotrophic factor19.5

Hyaluronic acid (average amount of 8.7 μg/mL) was detected in the formulated Wharton's jelly. The nanoparticle tracking analysis demonstrated the presence of billions of particles (average amount of 17.4 billion/mL) in the extracellular vesicles size range in the light scattering mode. CellMask Orange™ staining showed the presence of 4.18 billion particles/mL in the fluorescent mode, indicative of true membrane-enclosed particles, i.e. extracellular vesicles. Representative images for nanoparticle tracking analysis in the light scattering and fluorescent mode are shown as Fig. [1](#Fig1){ref-type="fig"}a and b, respectively. Fig. 1**a** A representative nanoparticle tracking analysis showed the presence of 9.90 ± 0.32 billion particles/mL in the light scattering mode with a mode size of 136.3 ± 8.2 nm. **b** A representative nanoparticle tracking analysis showed the presence of 4.90 ± 0.08 billion particles/mL in the fluorescent mode with a mode size of 137.9 ± 4.0 nm. Values are shown as mean ± standard error

Discussion {#Sec4}
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Biologics hold great potential in treating a variety of musculoskeletal ailments \[[@CR6]\]. At present, the published literature related to umbilical cord-derived Wharton's jelly focuses on the isolated cells, and despite the commercial use, there is still insufficient characterization of these formulations \[[@CR18], [@CR20], [@CR21]\]. In the present study, we formulated a novel umbilical cord-derived Wharton's jelly product and evaluated it for the presence of growth factors, cytokines, hyaluronic acid and extracellular vesicles including exosomes. The essential components of regenerative medicine, namely growth factors, cytokines, hyaluronic acid and extracellular vesicles, are all present in the formulated Wharton's jelly. The results from this study are an essential preliminary first step to better characterize Wharton's jelly. This is necessary to perform clinical trials to determine safety and efficacy of this novel formulation for regenerative medicine applications.

Numerous growth factors were detected in our Wharton's jelly formulation. We detected IGFBP 1, 2, 3, 4 and 6, which acts as a carrier protein for insulin-like growth factor -- 1 (IGF-1). IGF-1 improves osteogenic differentiation, induces chondrogenic differentiation of mesenchymal stem cells, and stimulates extracellular matrix production \[[@CR22]\]. We also detected TGF-α, a transforming growth factor which is a ligand for the epidermal growth factor receptor (EGFR). EGFR promotes proliferation and survival of osteoprogenitors and plays an anabolic role in bone metabolism \[[@CR23]\]. In addition, platelet-derived growth factor-AA (PDGF-AA), a potent mitogen for cells of mesenchymal origin, was detected. PDGF-AA exhibits chemotactic effects toward human osteoblasts, and its downregulation is associated with cartilage degeneration \[[@CR24]\]. We also detected expression of vascular endothelial growth factor (VEGF), a signal protein produced by cells to stimulate blood vessel formation. VEGF is involved in bone tissue remodeling and new bone formation and is downregulated in patients with osteoarthritis \[[@CR25]\].

Several immunomodulatory cytokines essential for regenerative medicine were identified. We detected high levels of chemokine (C-C motif) ligand 5 (CCL5), also known as RANTES (regulated on activation, normal T cell expressed and secreted), which has been reported to be involved in modulation of macrophage phenotype from M1 (pro-inflammatory) to M2 (tissue healing) leading to enhanced osteogenesis \[[@CR26]\]. RANTES also plays a vital role in chemotaxis, survival of osteoblasts and bone remodeling \[[@CR27]\]. We also observed expression of interleukin 6 receptor (IL-6R). IL-6 plays an important role in immune regulation and tissue regeneration, and, when binding with IL-6R, it activates the downstream STAT3 signaling pathway that promotes osteogenic differentiation in mesenchymal stem cells via autocrine/paracrine feedback loop \[[@CR28]\].

We detected pro-inflammatory and anti-inflammatory cytokines in the formulated Wharton's jelly. Pro-inflammatory cytokines usually exert deleterious effects, including mediation of foreign body response and initiating inflammatory response against implants leading to their premature failure. Recent studies have explored their potential as initiators of regeneration. These studies have proposed a pro-regenerative function of the inflammatory signals initiated by these cytokines, and that a proper sequence of inflammatory signals followed by anti-inflammatory signals is essential for proper healing \[[@CR29]\]. We detected macrophage colony-stimulating factor (MCSF), as well as macrophage stimulating protein 1-alpha (MIP1-α), which are essential for osteoclast formation \[[@CR30], [@CR31]\]. Osteoclasts play a vital role during early bone healing: they maintain and improve the structural strength of bone tissue in conjunction with osteoblasts in a fine adjusted system \[[@CR32]\].

We also identified interleukin 1 receptor antagonist (IL-1RA), a specific interleukin-1 (IL-1) receptor antagonist that competitively binds to the same receptor as IL-1 (including inflammatory IL-α and IL-1β), thereby blocking IL-1 mediated cellular changes \[[@CR33]\]. IL-1RA attenuates or prevents cytokine-mediated inflammatory hyperalgesia \[[@CR34]\]. Intraarticular injection of IL-1RA in patients with knee osteoarthritis slow its progression while improving pain and WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) global score \[[@CR35]\]. We detected homeostatic cytokines, tissue inhibitor of metalloproteinases (TIMP) 1 and 2, which regulate the activity of matrix metalloproteinases (MMP) \[[@CR36]\]. MMPs can degrade all components of connective tissue at physiological pH and may be involved in bone matrix degradation \[[@CR37]\]. TIMPs are downregulated in aged tendons, and mechanical stresses, including injuries, further reduce their levels \[[@CR38]\]. In addition, TIMPs regulate several biological processes such as cell growth, differentiation and apoptosis that are independent of its MMP activity \[[@CR39]\].

We identified several cytokines involved in wound healing. For example, we detected intercellular adhesion molecule-1 (ICAM-1), which promotes leukocyte accumulation into the wound site required for wound healing \[[@CR40]\]. ICAM-1 also has immunosuppressive effects on dendritic cells and T cells, which may aid in the treatment of graft versus host diseases \[[@CR41]\]. We detected expression of monocyte chemotactic protein-1 (aka CCL2), a pro-inflammatory cytokine, which promotes wound healing, including in hard to heal diabetic wounds \[[@CR42]\]. We detected growth differentiation factor 15 (GDF-15), one of the members of transforming growth factor beta superfamily, which modulates bone microenvironment, including suppression of formation or activation of osteoclasts leading to accumulation of bone matrix \[[@CR43]\]. We also detected regenerative cytokines, including growth hormone, which stimulates cell growth, reproduction and regeneration, and plays an important role in cartilage regeneration \[[@CR44]\].

We detected expression of hyaluronic acid. The umbilical cord tissue contains high molecular weight hyaluronic acid (HMW), which is associated with high fluid retention in joints and has strong anti-inflammatory properties \[[@CR45]\]. In addition, it is useful in the management of knee osteoarthritis via its chondroprotection, proteoglycan and glycosaminoglycan synthesis, and anti-inflammatory, mechanical, subchondral, and analgesic actions \[[@CR10]\]. Hyaluronic acid accelerates tendon-to-bone healing after rotator cuff repair and has shown potential in the treatment of enthesopathies such as lateral epicondylitis, patellar tendinopathy, insertional Achilles tendinopathy and plantar fasciitis \[[@CR46]\].

We also detected the presence of membrane-enclosed particles in the extracellular vesicle size range. Extracellular vesicles including exosomes have demonstrated potential anti-inflammatory and pro-regenerative effects essential for inducing healing in different tissue types \[[@CR47]\]. They positively affect cell proliferation and viability, angiogenesis, and immunomodulation in different physiological systems \[[@CR47]\]. Exosome uptake by cells significantly reduces pro-inflammatory gene expression and level of M1 phenotypic marker, increase cell migration, and increase expression of osteogenic markers, which play a unique osteo-immunomodulatory role in regulation of bone dynamics \[[@CR48]\]. Exosomes stimulate secretion of favorable cellular factors required to accelerate the healing response for tendon injuries including rotator cuff tears \[[@CR49], [@CR50]\]. Exosomes also promote cartilage repair and chondrocyte proliferation in osteoarthritis \[[@CR51]\].

These results confirmed our hypothesis that growth factors, cytokines, hyaluronic acid, and extracellular vesicles are present in the formulated Wharton's jelly. Several published basic science and preliminary clinical studies indicate that the combination of these factors may have added advantages for regenerative medicine applications \[[@CR46]\]. For example, a co-injection of growth hormone and hyaluronic acid was more effective in treating osteoarthritis compared with injections of hyaluronic acid alone \[[@CR52]\], demonstrating the advantage of different factors in one formulation.

We also compared the amount of growth factors, cytokines, hyaluronic acid, and exosomes in Wharton's jelly with other biologics based on the published literature. The amount of growth factors in Wharton's jelly is higher compared with the umbilical cord artery \[[@CR18]\]. Jin et al. demonstrated biological advantages of umbilical cord-derived tissue compared with bone marrow- and adipose-derived tissue \[[@CR53]\]. Wharton's jelly-derived tissue offers many advantages over bone marrow-derived tissue \[[@CR54]\]. This is attributed to upregulation of genes involved in wound healing and immune response in Wharton's jelly compared with bone marrow-derived tissue \[[@CR54]\]. Amable et al. demonstrated higher expression of factors including RANTES, MCP-1, IL-1RA, and PDGF-AA in supernatant derived from Wharton's jelly stromal cells compared with bone marrow- and adipose-derived stromal cell supernatant \[[@CR55]\]. The amount of VEGF, MCSF, RANTES and MCP-1 is higher in our formulation compared with the amount reported by Amable et al. in the activated platelet-rich plasma (PRP) in another study \[[@CR56]\]. Cryopreserved amniotic membrane secreted intermediate levels of TIMP1 and TIMP2, low levels of MCP-1, and no detectable levels of RANTES \[[@CR57]\]. In contrast, our formulation expressed high levels of these growth factors and cytokines. The amount of hyaluronic acid detected in our formulation is much higher compared with the amount found in amniotic fluid \[[@CR58]\]. Other biologics, such as PRP and bone marrow aspirate concentrate, lack hyaluronic acid. Combining these biologics with hyaluronic acid can further improve the functional outcomes in the management of knee osteoarthritis \[[@CR59]\]. The total exosome yield adjusted to 1 million mesenchymal stem cells was 1.3 times higher in amniotic fluid compared with bone marrow \[[@CR60]\]. The amount of exosome particles/mL released by 1 million amniotic fluid stem cells is estimated to be 0.3 billion \[[@CR61]\]. In contrast, the amount of exosome particles/mL adjusted to 1 million Wharton's jelly mesenchymal stem cells is around 4 billion \[[@CR62]\], higher than both amniotic fluid- and bone marrow-derived stem cells. The amount of growth factors, cytokines, hyaluronic acid, and exosomes in Wharton's jelly are therefore higher compared with other biologics.

Our study has several limitations. Basic science studies have demonstrated the presence of a large number of growth factors in Wharton's jelly \[[@CR18]\]. However, the assay kits used in our analysis can detect only 40 growth factors and 40 cytokines. Future studies are required to determine other growth factors and cytokines expressed in this formulation. Another limitation is the possible presence of microvesicles in addition to the exosomes in the detected extracellular vesicles. Further analysis is needed to confirm the presence of exosomes using exosome-specific markers via immunoblotting assay. In addition to hyaluronic acid, the extracellular matrix of Wharton's jelly contains a significant amount of collagen and sulphated glycosaminoglycans required for regenerative medicine applications \[[@CR20], [@CR21]\]. Future studies are required to determine the amount of these extracellular matrix components in our formulation and examine their benefits.

Conclusion {#Sec5}
==========

Our Wharton's jelly formulation demonstrated the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles in clinically relevant quantities, in amounts greater compared with other biologics. The presence of multiple factors within one formulation may help reduce inflammation, decrease pain and augment healing of musculoskeletal injuries. These factors represent potential expanded applications for regenerative medicine.
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